Low uptake of Merck's Zostavax costing healthcare systems

Merck's ($MRK) shingles vaccine Zostavax is still reaching too few people, a Duke University associate professor warns. Sales soared last year after Merck overcome supply constraints, but there is still room for growth. Fewer than 20% of Americans ages 60 and older have received the vaccine. Item

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.